Dupilumab
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Dupilumab: From Atopic Dermatitis to Bronchitis
One-Sentence Summary
Dupilumab is an IL-4Rα-blocking monoclonal antibody, originally used to treat atopic dermatitis (eczema). The TxGNN model predicts it may be effective for bronchitis (most likely type 2 airway disease and COPD with chronic bronchitis features), with 1 clinical trial (an indirect one in chronic rhinosinusitis) and 11 publications currently supporting this direction. The evidence is indirect and should be treated as a research question rather than a ready-to-use indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic dermatitis (atopic eczema) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Note: The Singapore registration records compiled for this report do not include approved-indication text. The original indication above comes from the knowledge-graph indication data.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the data compiled for this report. Based on the literature, dupilumab binds the IL-4 receptor alpha subunit, which blocks both IL-4 and IL-13 signalling. These are two key drivers of type 2 inflammation.
Atopic dermatitis is a type 2 inflammatory disease. Several airway diseases share this pathway, including eosinophilic asthma, COPD with a type 2 (eosinophilic) phenotype, and eosinophilic plastic bronchitis. This is the mechanistic bridge from the original indication to the prediction.
"Bronchitis" is a non-specific label. It probably captures COPD with a chronic bronchitis phenotype and type 2 airway disease, so the evidence should be assessed by subpopulation. It should not be read as support for acute or infectious bronchitis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04362501 | Phase 2 | Completed | 33 | Randomized, placebo-controlled study of dupilumab in chronic rhinosinusitis without nasal polyps. This is an upper-airway type 2 disease, so the link to bronchitis is indirect. |
No trial tests dupilumab directly in bronchitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34597534 | 2022 | RCT (extension) | Lancet Respir Med | TRAVERSE open-label extension: long-term safety and efficacy of dupilumab in moderate-to-severe asthma beyond 1 year |
| 30273510 | 2019 | Meta-analysis | J Asthma | Pooled RCTs of dupilumab versus placebo in uncontrolled asthma, assessing efficacy and safety |
| 42617837 | 2026 | Comparative cohort | Chest | Matching-adjusted indirect comparison: mepolizumab and dupilumab showed no significant difference in reducing exacerbations in eosinophilic COPD |
| 42839285 | 2026 | Real-world cohort | Respir Res | German multicentre real-world analysis of dupilumab in COPD |
| 42511891 | 2026 | Real-world case series | Biomedicines | 12 patients with type 2 COPD (predominantly chronic bronchitis phenotype) treated with dupilumab under compassionate use |
| 39904363 | 2025 | Review | Tuberc Respir Dis | Review of pharmacologic therapies to prevent COPD exacerbations |
| 42773542 | 2026 | Review | Eur J Clin Invest | Review of COPD management from inflammatory pathways to targeted therapies |
| 38488768 | 2024 | Review | Pediatr Pulmonol | Novel therapies for eosinophilic pediatric plastic bronchitis |
| 30196731 | 2018 | Review | Expert Opin Pharmacother | Managing asthma associated with smoking-induced airway diseases, including chronic bronchitis |
| 32428511 | 2020 | Clinical study (imaging) | Chest | Anti-T2 biologic effects on lung ventilation by MRI in prednisone-dependent asthma |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15675P | DUPIXENT solution for injection in a pre-filled syringe 300 mg/2 ml | Injection, solution | Not available in the registration record |
| SIN16121P | DUPIXENT solution for injection in a pre-filled syringe 200 mg/1.14 ml | Injection, solution | Not available in the registration record |
Safety Considerations
- Drug Interactions: 53 interactions were recorded. Major-level interactions include adalimumab, baricitinib, certolizumab pegol and cladribine. Moderate-level examples include warfarin, roflumilast, azathioprine, cyclosporine, anakinra, denosumab and dimethyl fumarate. Zinc salts are minor.
- Other signals from the literature: Conjunctivitis, head and neck dermatitis, and paradoxical psoriasiform or pustular eruptions have been reported with dupilumab.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No trial tests dupilumab directly in bronchitis, and the only listed trial is a small Phase 2 study in an upper-airway disease. The supporting literature is mostly asthma RCTs, COPD real-world cohorts and reviews. The signal is real for type 2 COPD and eosinophilic airway disease, but "bronchitis" is too non-specific to act on as one indication.
To proceed, the following is needed:
- Redefine the target population, for example COPD with a type 2 (eosinophilic) phenotype or eosinophilic bronchitis, instead of the generic "bronchitis"
- Review the COPD-specific pivotal trial data and the regulatory status of dupilumab in COPD in Singapore
- Obtain the HSA package insert, including approved indications, warnings and contraindications
- Obtain detailed mechanism-of-action data
- Set up a safety monitoring plan, including ocular adverse events and interactions with immunosuppressants and biologics
Other Predicted Indications (Brief Summary)
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation | Notes | |------|------|------|------|------|------| | 2 | Dermatitis | 99.71% | L1 | Proceed with Guardrails | Multiple completed Phase 3 RCTs (for example NCT02755649, NCT02395133, NCT04417894, NCT03912259) and landmark publications (SOLO 1/2, CHRONOS). This is largely the already-approved atopic dermatitis indication, not a true repurposing. Monitor head and neck dermatitis, immunogenicity and inadequate response. | | 3 | Acne keloid | 99.61% | L4 | Hold | One case-level publication on keloid stabilization; no trials; no acne-specific evidence. | | 4 | Exanthem | 99.57% | L3 | Research Question | One small Phase 4 study (n=10) and a systematic review in cutaneous immune-related adverse events. Evidence is mixed because dupilumab can also induce rashes. | | 5–10 | Neonatal dermatomyositis; acrodermatitis chronica atrophicans; amyopathic dermatomyositis; childhood connective-tissue-disease-associated ILD; familial hydroa vacciniforme; severe nonproliferative diabetic retinopathy | 99.09–99.56% | L5 | Hold | Model prediction only, with no valid trials or literature and no plausible mechanistic link. |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.